Sanofi (SNY)
Pre-Market:
| Previous Close | 49.01 |
| Open | 49.25 |
| Bid | 49.29 x 400 |
| Ask | 49.36 x 400 |
| Day's Range | 48.98 - 49.45 |
| 52 Week Range | 42.63 - 55.72 |
| Volume | |
| Avg. Volume | 2,089,880 |
| Market Cap | 123.15B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 25.43 |
| EPS (TTM) | 1.94 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 2.04 (4.13%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 58.92 |
BloombergBofA, BNP Poised to Win Lead Roles on $20 Billion Sanofi Spinoff
(Bloomberg) -- Bank of America Corp. and BNP Paribas SA are on the verge of winning lead roles arranging Sanofi’s separation of its consumer-health business, according to people familiar with the matter, in one of the year’s most sought-after banking assignments. Most Read from BloombergIsrael Says a Cease-Fire Plan Backed by Hamas Falls Far ShortAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeEx-Trump Controller Says Cohen Repaid From Personal AccountJack Dorsey Leaves Bluesky B
Insider MonkeyRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $9.55 EPS, expectations were $10.17. Regeneron Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]
- Thomson Reuters StreetEvents
Q1 2024 Kymera Therapeutics Inc Earnings Call
Q1 2024 Kymera Therapeutics Inc Earnings Call
